Federico Ravaioli

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 108 publications

Author's reply: ``Survival fragility in advanced hepatocellular carcinoma immunotherapy trials requires clinical context''.

Author's reply: ``Survival fragility in advanced hepatocellular carcinoma immunotherapy trials requires clinical context''.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: July 13, 2026

Complementary evaluation of phase III immunotherapy trials in advanced HCC using the survival-inferred fragility index.

Complementary evaluation of phase III immunotherapy trials in advanced HCC using the survival-inferred fragility index.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: January 16, 2026

Reply: Beyond semantics-Acknowledging diagnostic differences between NAFLD and MASLD.

Reply: Beyond semantics-Acknowledging diagnostic differences between NAFLD and MASLD.

Journal: Hepatology (Baltimore, Md.)
Published: November 28, 2025

IMAT-HCC model: Liver stiffness-enhanced integrated risk stratification for HCC recurrence after resection.

IMAT-HCC model: Liver stiffness-enhanced integrated risk stratification for HCC recurrence after resection.

Journal: JHEP reports : innovation in hepatology
Published: September 15, 2025

HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients.

HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients.

Journal: Journal of hepatocellular carcinoma
Published: August 21, 2025

Concomitant Autoimmune Liver Disease and Hepatic Actinomycosis: A Diagnostic Challenge-Brief Report and Review of the Literature.

Concomitant Autoimmune Liver Disease and Hepatic Actinomycosis: A Diagnostic Challenge-Brief Report and Review of the Literature.

Journal: International journal of molecular sciences
Published: August 21, 2025

Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease.

Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease.

Journal: Journal of hepatology
Published: July 31, 2025

Spleen stiffness measurement rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis.

Spleen stiffness measurement rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis.

Journal: Journal of hepatology
Published: June 11, 2025

Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST.

Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST.

Journal: Hepatology (Baltimore, Md.)
Published: May 28, 2025

Dietary Strategies to Modulate Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Dietary Strategies to Modulate Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Journal: Nutrients
Published: May 10, 2025

Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD.

Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD.

Journal: Journal of hepatology
Published: April 23, 2025

What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?

What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?

Journal: Expert review of gastroenterology & hepatology
Published: March 05, 2025
Showing 1-12 of 108

Last Updated: 09/26/2026